Investor Casdin Capital, LLC
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Casdin Capital, LLC . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Add This Fund
to your dashboard

Date Form Target Prev
Shares		 Current
Shares		 Change
(Percent)		 Ownership
(Percent)		 Change
(Percent)
2025-08-21 13D/A BLFS / BioLife Solutions, Inc. 7,207,165 6,707,165
2025-08-14 13G/A CDXS / Codexis, Inc. 8,100,000 7,200,000
2025-08-13 13D/A BLFS / BioLife Solutions, Inc. 7,707,165 7,207,165
2025-06-12 13D/A BLFS / BioLife Solutions, Inc. 8,735,159 7,707,165
2025-05-15 13G/A IPSC / Century Therapeutics, Inc. 4,592,316 3,212,316
2025-04-09 13D/A BLFS / BioLife Solutions, Inc. 8,707,165 8,735,159
2025-03-07 13D/A TNYA / Tenaya Therapeutics, Inc. 6,427,200 6,732,971
2025-03-04 13D/A LAB / Standard BioTools Inc. 73,766,074 80,864,315
2025-02-14 13G/A NGNE / Neurogene Inc. 1,024,616 1,295,361
2024-11-27 13G IPSC / Century Therapeutics, Inc. 3,212,316 4,592,316
2024-11-14 13G/A IPSC / Century Therapeutics, Inc. 5,190,506 3,212,316
2024-11-08 13G NGNE / Neurogene Inc. 1,024,616
2024-09-26 13G CDXS / Codexis, Inc. 0 8,100,000
2024-08-14 13D/A LAB / Standard BioTools Inc. 70,401,337 73,766,074
2024-06-03 13D/A LAB / Standard BioTools Inc. 76,337,738 70,401,337
2024-05-22 13D/A LAB / Standard BioTools Inc. 74,535,666 76,337,738
2024-04-18 13G IPSC / Century Therapeutics, Inc. 3,206,380 5,190,506
2024-04-08 13D/A IPSC / Century Therapeutics, Inc. 3,222,940 3,206,380
2024-03-20 13D/A LAB / Standard BioTools Inc. 65,297,596 74,535,666
2024-02-14 13G/A MXCT / MaxCyte, Inc. 9,220,000 0
2024-02-14 13G/A RLAY / Relay Therapeutics, Inc. 6,298,574 7,387,943
2024-01-09 13D/A LAB / Standard BioTools Inc. 37,582,346 65,297,596
2023-11-15 13D/A EQRX / EQRx Inc 56,297,042 0
2023-10-24 13D/A BLFS / BioLife Solutions, Inc. 7,440,107 8,707,165
2023-10-02 13G RLAY / Relay Therapeutics, Inc. 6,298,574
2023-05-08 13D/A ABSI / Absci Corporation 5,533,260 4,448,260
2023-03-20 13D/A ABSI / Absci Corporation 6,473,260 5,533,260
2023-02-14 13G/A NVTAQ / Invitae Corporation 12,203,669 9,038,388
2023-02-14 13G/A TNGX / Tango Therapeutics, Inc. 5,487,910 0
2023-02-14 13G/A CDXS / Codexis, Inc. 4,330,000 0
2023-02-14 13G/A DMTKQ / DermTech, Inc. 1,745,000 0
2023-02-14 13G/A MGTA / Magenta Therapeutics Inc 3,901,589 0
2023-02-14 13G/A VERV / Verve Therapeutics, Inc. 3,138,167 2,290,571
2023-02-13 13D/A ABSI / Absci Corporation 7,718,593 6,473,260
2023-01-10 13G/A MXCT / MaxCyte, Inc. 13,971,334 9,220,000
2022-12-07 13D/A TNYA / Tenaya Therapeutics, Inc. 6,427,200 6,427,200
2022-11-29 13D/A EQRX / EQRx Inc 56,297,042
2022-11-28 13D/A TNYA / Tenaya Therapeutics, Inc. 3,586,818 6,427,200
2022-10-11 13D/A IPSC / Century Therapeutics, Inc. 3,246,124 3,222,940
2022-07-21 13D/A ABSI / Absci Corporation 7,718,593 7,718,593
2022-04-08 13D LAB / Standard BioTools Inc. 37,582,346
2022-02-14 13G/A VERV / Verve Therapeutics, Inc. 3,038,167 3,138,167
2022-02-14 13G/A NVTA / Invitae Corporation 12,298,038 12,203,669
2022-02-14 13G/A DMTK / DermTech, Inc. 1,370,000 1,745,000
2022-02-14 13G/A MGTA / Magenta Therapeutics Inc 3,346,035 3,901,589
2021-08-19 13G TNGX / Tango Therapeutics, Inc. 5,487,910
2021-08-09 13D TNYA / Tenaya Therapeutics, Inc. 3,586,818
2021-08-03 13G MXCT / MaxCyte, Inc. 13,971,334
2021-07-29 13D IPSC / Century Therapeutics, Inc. 3,246,124
2021-07-29 13D ABSI / Absci Corporation 7,718,593
2021-06-23 13G VERV / Verve Therapeutics, Inc. 3,038,167
2021-02-11 13G/A GRTS / Gritstone bio, Inc. 2,160,000 0
2021-02-11 13G/A MGTA / Magenta Therapeutics Inc 3,098,122 3,346,035
2021-02-11 13G/A FULC / Fulcrum Therapeutics, Inc. 1,239,285 1,241,176
2021-02-11 13G/A NVTA / Invitae Corporation 9,033,943 12,298,038
2021-02-11 13G/A DMTK / DermTech, Inc. 1,428,571 1,370,000
2021-02-11 13G/A CDXS / Codexis, Inc. 5,073,780 4,330,000
2020-11-27 13D BLFS / BioLife Solutions, Inc. 4,373,333 7,440,107
2020-06-01 13G DMTK / DermTech, Inc. 1,428,571
2020-05-19 13G/A BLFS / BioLife Solutions, Inc. 4,373,333 4,373,333
2020-05-18 13G/A BLFS / BioLife Solutions, Inc. 2,468,571 4,373,333
2020-05-18 13D/A US3723091043 / GenMark Diagnostics, Inc 3,365,000 2,555,000
2020-04-07 13G NVTA / Invitae Corporation 9,033,943
2020-02-20 13G FULC / Fulcrum Therapeutics, Inc. 1,239,285
2020-02-07 13D/A US3723091043 / GenMark Diagnostics, Inc 3,850,000 3,365,000
2020-02-06 13G/A US2103731061 / Constellation Pharmaceuticals Inc 1,556,999 1,212,734
2020-02-06 13G/A GRTS / Gritstone bio, Inc. 1,900,000 2,160,000
2020-02-06 13G/A MGTA / Magenta Therapeutics Inc 2,643,318 3,098,122
2020-02-06 13G/A BLFS / BioLife Solutions, Inc. 2,428,571 2,468,571
2019-11-21 13G GRTS / Gritstone bio, Inc. 1,900,000
2019-06-25 13G CDXS / Codexis, Inc. 5,073,780
2019-02-14 13G/A US2103731061 / Constellation Pharmaceuticals Inc 1,512,986 1,556,999
2019-02-14 13G/A MGTA / Magenta Therapeutics Inc 2,643,318
2018-10-31 13G US2103731061 / Constellation Pharmaceuticals Inc 1,512,986
2018-08-15 13G/A BLFS / BioLife Solutions, Inc. 2,035,818 2,428,571
2018-07-02 13G MGTA / Magenta Therapeutics Inc 2,035,818
2018-07-02 13G BLFS / BioLife Solutions, Inc. 1,000,000 2,035,818
2018-04-26 13G BLFS / BioLife Solutions, Inc. 1,000,000
2018-03-27 13D US3723091043 / GenMark Diagnostics, Inc 3,850,000